Key result
Preoperative levosimendan linked to ~28% lower PA pressure and less RV dilatation after cardiac surgery.
Why the study?
Does preoperative levosimendan improve cardiac, renal, and neurological parameters in high-risk patients with RV dysfunction and pulmonary hypertension undergoing cardiac valve surgery?
Population
27 high-risk cardiac patients with right ventricular dysfunction and pulmonary hypertension, scheduled for…
Design
Cohort
Follow-up
48 hours
Authors
Loading...
May improve RV parameters without renal/neurological harm in high-risk valve surgery; hypothesis-generating and requires RCTs before practice change.
Observational (n=27)
Does preoperative levosimendan improve cardiac, renal, and neurological parameters in high-risk patients with RV dysfunction and pulmonary hypertension undergoing cardiac valve surgery?
Preoperative levosimendan in high-risk patients with RV dysfunction undergoing valve surgery improved RV parameters without significant worsening of renal or neurological biomarkers at 48 hours.
Guerrero-Orriach et al. (2016) conducted an observational in Right ventricular dysfunction and pulmonary hypertension (n=27). Preoperative levosimendan was evaluated on Cardiac function, renal function (N-GAL), and neuronal damage (neuron-specific enolase). Preoperative levosimendan administration in high-risk cardiac surgery patients decreased RV dilatation (4.23 to 3.45 mm) and pulmonary artery pressure (58 to 42 mmHg) at 48 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: